Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

被引：430
作者：
Dinulescu D.M. [1 ,2 ]
Ince T.A. [3 ,4 ]
Quade B.J. [4 ]
Shafer S.A. [1 ,2 ]
Crowley D. [1 ,2 ]
Jacks T. [1 ,2 ]
机构：
[1] Center for Cancer Research, MA Institute of Technology, Cambridge, MA 02139
[2] Department of Biology, MA Institute of Technology, Cambridge, MA 02139
[3] Whitehead Institute, Nine Cambridge Center, Cambridge
[4] Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115
来源：
Nature Medicine | 2005年 / 11卷 / 1期
关键词：
D O I：
10.1038/nm1173
中图分类号：
学科分类号：
摘要：
Epithelial ovarian tumors present a complex clinical, diagnostic and therapeutic challenge because of the difficulty of early detection, lack of known precursor lesions and high mortality rates. Endometrioid ovarian carcinomas are frequently associated with endometriosis, but the mechanism for this association remains unknown. Here we present the first genetic models of peritoneal endometriosis and endometrioid ovarian adenocarcinoma in mice, both based on the activation of an oncogenic K-ras allele. In addition, we find that expression of oncogenic K-ras or conditional Pten deletion within the ovarian surface epithelium gives rise to preneoplastic ovarian lesions with an endometrioid glandular morphology. Furthermore, the combination of the two mutations in the ovary leads to the induction of invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance and a disease latency of only 7 weeks. The ovarian cancer model described in this study recapitulates the specific tumor histomorphology and metastatic potential of the human disease.
引用
收藏
页码：63 / 70
页数：7
相关论文
共 22 条
  • [1] Ozols R.F., Et al., Focus on epithelial ovarian cancer, Cancer Cell, 5, pp. 19-24, (2004)
  • [2] Obata K., Et al., Frequent PTEN/MMAC1 mutations in endometrioid but not serous or mucinous epithelial ovarian tumors, Cancer Res., 58, pp. 2095-2097, (1998)
  • [3] Sato N., Et al., Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: Possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary, Cancer Res., 60, pp. 7052-7056, (2000)
  • [4] Cuatrecasas M., Et al., K-ras mutations in nonmucinous ovarian epithelial tumors, Cancer, 82, pp. 1088-1095, (1998)
  • [5] Gemignani M.L., Et al., Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma, Gynecol. Oncol., 90, pp. 378-381, (2003)
  • [6] Hogdall E.V., Et al., K-ras alterations in Danish ovarian tumor patients. From the Danish "Malova" Ovarian cancer study, Gynecol. Oncol., 89, pp. 31-36, (2003)
  • [7] Okuda T., Okai T., p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer, Gynecol. Oncol., 88, pp. 318-325, (2003)
  • [8] Orsulic S., Et al., Induction of ovarian cancer by defined multiple genetic changes in a mouse model system, Cancer Cell, 1, pp. 53-62, (2002)
  • [9] Connolly D.C., Et al., Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer, Cancer Res., 63, pp. 1389-1397, (2003)
  • [10] Flesken-Nikitin A., Choi K.C., Eng J.P., Shmidt E.N., Nikitin A.Y., Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium, Cancer Res., 63, pp. 3459-3463, (2003)
123